P & G Health Ltd
Drug Manufacturers - Specialty & Generic · PGHL
Mid CapHealthcareMature Stable
Milind Thatte
Managing Director · Transformational
Company DNA
Bureaucratic
About
P & G Health Ltd is a Mid Cap company in the Healthcare sector, listed on NSE as PGHL. With a market cap of ₹8K Cr and revenue of —, it is currently in the Mature Stable phase. Known for its Bureaucratic culture and Traditionalist approach to innovation, the company operates at a Steady-Marathon pace. A subsidiary of a major multinational, adhering to strictly documented global compliance, quality control, and rigorous internal administrative processes. Its strategic mandate: Focus must shift towards deepening brand penetration and patient-centric health solutions in a highly regulated pharmaceutical environment.
FAQ
What kind of company is P & G Health Ltd?
P & G Health Ltd is a Mid Cap Healthcare company (PGHL) in the Mature Stable phase with a market cap of ₹8K Cr. It is classified as Bureaucratic in culture.
What is P & G Health Ltd's culture and work environment like?
P & G Health Ltd has a Bureaucratic culture with Traditionalist innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: Mass-Consumer. A subsidiary of a major multinational, adhering to strictly documented global compliance, quality control, and rigorous internal administrative processes.
Who leads P & G Health Ltd?
P & G Health Ltd is led by Milind Thatte (Managing Director), a Transformational leader with 30 years of experience.
Culture & Strategy
CultureBureaucratic
InnovationTraditionalist
PaceSteady-Marathon
PurposePurpose-Blended
CustomerMass-Consumer
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
A subsidiary of a major multinational, adhering to strictly documented global compliance, quality control, and rigorous internal administrative processes.
Mandate
Focus must shift towards deepening brand penetration and patient-centric health solutions in a highly regulated pharmaceutical environment.
Focus must shift towards deepening brand penetration and patient-centric health solutions in a highly regulated pharmaceutical environment.
Financials
Revenue FY25—
PAT FY25—
Rev CAGR 5Y4.5%
OPM—
NPM17.8%
ROE37.3%
ROCE48.5%
P/E34
Fwd P/E25.6
P/B13
D/E1
Mkt Cap₹8K Cr
Promoter52.2%
Institutional16%
Similar Culture
Could You Lead P & G Health Ltd?
Take the Genome Benchmark →